Detalhe da pesquisa
1.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(2): 223-234, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539742
2.
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
J Clin Oncol
; 41(6): 1193-1199, 2023 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36508302
3.
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Blood
; 116(12): 2026-32, 2010 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-20551376
4.
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
JAMA Oncol
; 6(6): 872-880, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32352505
5.
The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma.
Curr Hematol Malig Rep
; 6(3): 164-71, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21553348